US6043057A
(en)
*
|
1988-09-16 |
2000-03-28 |
Vitec Aktiebolag |
Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
|
IT1253009B
(it)
*
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
|
GB9513371D0
(en)
|
1995-06-30 |
1995-09-06 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9326174D0
(en)
*
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6436407B1
(en)
|
1994-08-26 |
2002-08-20 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant
|
US6019982A
(en)
*
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
GB9603314D0
(en)
*
|
1996-02-16 |
1996-04-17 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
AU9120898A
(en)
|
1997-08-27 |
1999-03-16 |
Chiron Corporation |
Molecular mimetics of meningococcal b epitopes
|
US6033673A
(en)
*
|
1998-03-18 |
2000-03-07 |
The Administrators Of Tulane Educational Fund |
Double mutant enterotoxin for use as an adjuvant
|
WO1999047165A1
(fr)
*
|
1998-03-18 |
1999-09-23 |
The Administrators Of The Tulane Educational Fund |
Production d'enterotoxine mutante purifiee prevue pour etre utilisee comme adjuvant
|
ES2304065T3
(es)
|
1998-05-01 |
2008-09-01 |
Novartis Vaccines And Diagnostics, Inc. |
Antigenos y composiciones de neisseria meningitidis.
|
US6576244B1
(en)
|
1998-06-19 |
2003-06-10 |
Acambis, Inc. |
LT and CT in parenteral immunization methods against helicobacter infection
|
JP4673974B2
(ja)
*
|
1998-09-30 |
2011-04-20 |
ワイス・ホールディングズ・コーポレイション |
アジュバントとしての変異コレラホロトキシン
|
AU773953B2
(en)
*
|
1998-12-22 |
2004-06-10 |
Boyce Thompson Institute For Plant Research Inc. |
Orally immunogenic bacterial enterotoxins expressed in transgenic plants
|
EP1141313A2
(fr)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Expression amelioree de polypeptides hiv et production de particules de type viral
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
CA2689696C
(fr)
|
1999-02-26 |
2013-08-06 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions a macromolecules et microparticules adsorbees
|
PT1154793E
(pt)
|
1999-02-26 |
2010-12-21 |
Novartis Vaccines & Diagnostic |
Utilização de bioadesivos e adjuvantes para a administração de antigénios nas mucosas
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
AU2001247522A1
(en)
*
|
2000-03-17 |
2001-10-03 |
Uab Research Foundation |
Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediatedor humoral immunity
|
US7063852B2
(en)
|
2000-05-19 |
2006-06-20 |
The Administrators Of The Tulane Educational Fund |
Hybrid LT-A/CT-B holotoxin for use as an adjuvant
|
EP1315816B1
(fr)
*
|
2000-09-08 |
2010-12-29 |
University Of Maryland Biotechnology Institute |
Vaccins a base d'adn a co-expression con us par genie genetique, leurs procedes de realisation et leurs utilisations
|
US20030162733A1
(en)
*
|
2000-11-27 |
2003-08-28 |
Haynes Joel R. |
Nucleic acid adjuvants
|
EP1363663B1
(fr)
|
2001-01-12 |
2011-03-02 |
Novartis Vaccines and Diagnostics, Inc. |
Immunisation des muqueuses par acide nucleique
|
EP2261241A1
(fr)
|
2001-04-16 |
2010-12-15 |
Wyeth Holdings Corporation |
Cadres de lecture ouverts de streptococcus pneumoniae codant pour des antigenes polypeptidiques, et leurs utilisations
|
WO2002098369A2
(fr)
|
2001-06-07 |
2002-12-12 |
Wyeth Holdings Corporation |
Formes mutantes de l'holotoxine du cholera utilisees comme adjuvant
|
JP2004535187A
(ja)
|
2001-06-07 |
2004-11-25 |
ワイス・ホールデイングス・コーポレーシヨン |
アジュバントとしてのコレラホロトキシンの突然変異形
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
EP1411770A4
(fr)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
|
EP2280074A3
(fr)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
AU2003215316A1
(en)
|
2002-02-20 |
2003-09-09 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
BR0308441A
(pt)
|
2002-03-15 |
2005-01-18 |
Wyeth Corp |
Proteìna variante de p4 de haemophilus influenzae não tipificável, composição imunogênica, molécula de nucleotìdeo isolada, célula hospedeira, e, métodos para induzir uma resposta imune em um ser humano contra h. influenzae não tipificável, e para produzir uma proteìna variante de p4
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
CN101721697A
(zh)
|
2002-10-01 |
2010-06-09 |
诺华疫苗和诊断公司 |
抗癌及抗感染性疾病组合物及其使用方法
|
WO2004060396A2
(fr)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenes contenant des compositions de phospholipide
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
ES2328697T5
(es)
|
2003-06-02 |
2017-07-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US8071652B2
(en)
|
2003-08-21 |
2011-12-06 |
The Board Of Regents Of The University Of Texas System |
Method of treating irritable bowel syndrome
|
GB0325494D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Sbl Vaccin Ab |
Expression system
|
PT1701968E
(pt)
|
2003-12-17 |
2015-09-11 |
Wyeth Llc |
Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos
|
TWI357414B
(en)
|
2003-12-17 |
2012-02-01 |
Wyeth Llc |
Aβ immunogenic peptide carrier conjugates and meth
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
CN1953991A
(zh)
|
2004-05-21 |
2007-04-25 |
惠氏公司 |
变异的金黄色葡萄球菌纤连蛋白结合蛋白
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
US8445000B2
(en)
|
2004-10-21 |
2013-05-21 |
Wyeth Llc |
Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
|
EP2266602A3
(fr)
|
2004-11-01 |
2011-08-10 |
Novartis Vaccines and Diagnostics, Inc. |
Approches combinatoires destinées à produire des réponses immunitaires
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
ME01334B
(me)
|
2005-04-08 |
2013-12-20 |
Wyeth Llc |
Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
WO2008094188A2
(fr)
|
2006-07-17 |
2008-08-07 |
Anza Therapeutics, Inc. |
Procédés et compositions utilisant la listeria pour renforcer l'immunogénicité par primo-immunisation
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
US8877208B2
(en)
|
2008-05-23 |
2014-11-04 |
The Regents Of The University Of Michigan |
Multivalent nanoemulsion vaccines
|
EP2328928A2
(fr)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Epitope conservé d'hémagglutinine, anticorps contre l'épitope et procédés d'utilisation
|
EP2349209A2
(fr)
|
2008-09-26 |
2011-08-03 |
Nanobio Corporation |
Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
|
AR074273A1
(es)
|
2008-11-05 |
2011-01-05 |
Wyeth Corp |
Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
|
EP2346529B1
(fr)
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Immunogènes peptidiques m2e humains
|
CN102307477B
(zh)
|
2009-01-05 |
2015-07-29 |
埃皮托吉尼西斯股份有限公司 |
佐剂组合物及使用方法
|
WO2010104883A1
(fr)
|
2009-03-09 |
2010-09-16 |
Molecular Express, Inc. |
Procédés et compositions pour formulation liposomale d'antigènes et leurs utilisations
|
ITMI20090946A1
(it)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
Espressione di proteine ricombinanti
|
EP3020412B1
(fr)
|
2009-06-16 |
2017-10-11 |
The Regents of the University of Michigan |
Vaccins en nanoémulsion
|
CN102947452A
(zh)
|
2010-05-23 |
2013-02-27 |
艾杜罗生物科技公司 |
使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物
|
KR101609032B1
(ko)
|
2010-06-04 |
2016-04-04 |
와이어쓰 엘엘씨 |
스트렙토코커스 뉴모니아 백신 제제
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
RU2580620C2
(ru)
|
2010-08-23 |
2016-04-10 |
ВАЙЕТ ЭлЭлСи |
СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
|
PE20140173A1
(es)
|
2010-09-10 |
2014-02-20 |
Wyeth Llc |
Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
|
SE535625C2
(sv)
*
|
2010-10-28 |
2012-10-16 |
Toleranzia Ab |
Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
|
EA034702B1
(ru)
|
2011-04-26 |
2020-03-10 |
Молекулар Экспресс, Инк. |
Липосомные композиции
|
CN107837394A
(zh)
|
2011-06-24 |
2018-03-27 |
埃皮托吉尼西斯有限公司 |
作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
EP2780035A1
(fr)
|
2011-11-14 |
2014-09-24 |
Novartis AG |
Complexes immunogènes de carbomères polyanioniques et de polypeptides env et procédés de fabrication et d'utilisation de ceux-ci
|
MY198910A
(en)
|
2012-03-09 |
2023-10-02 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
WO2014008475A2
(fr)
|
2012-07-05 |
2014-01-09 |
The Ohio State University |
Compositions et procédés associés à des vaccins viraux
|
CN104854128A
(zh)
|
2012-07-19 |
2015-08-19 |
硕腾有限责任公司 |
牛流感病毒组合物
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
RU2724840C2
(ru)
|
2012-08-16 |
2020-06-25 |
Пфайзер Инк. |
Способы гликоконъюгирования и композиции
|
BR112015009229B1
(pt)
|
2012-10-24 |
2021-07-20 |
Platelet Targeted Therapeutics, Llc |
Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
|
KR20140075201A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2964665B1
(fr)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Polypeptides immunogènes de fusion
|
JP2016512841A
(ja)
|
2013-03-15 |
2016-05-09 |
ゾエティス・サービシーズ・エルエルシー |
多価ワクチンによるb.トレハロシ感染に対するウシの干渉効果
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
JP6306700B2
(ja)
|
2013-11-01 |
2018-04-04 |
ユニバーシティ オブ オスロUniversity of Oslo |
アルブミン改変体及びその使用
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(fr)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
|
SI3583947T1
(sl)
|
2014-01-21 |
2024-01-31 |
Pfizer Inc. |
Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
|
WO2015110940A2
(fr)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci
|
ES2930318T3
(es)
|
2014-02-14 |
2022-12-09 |
Pfizer |
Conjugados glucoproteicos inmunogénicos
|
EP4112076A1
(fr)
|
2014-10-10 |
2023-01-04 |
The Regents of The University of Michigan |
Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
|
CN107249626A
(zh)
|
2015-02-19 |
2017-10-13 |
辉瑞大药厂 |
脑膜炎奈瑟球菌组合物及其方法
|
EP4226937A3
(fr)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Virus non neuro-invasifs et leurs utilisations
|
US10624964B2
(en)
|
2015-05-01 |
2020-04-21 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
|
MX2018001841A
(es)
|
2015-08-14 |
2018-08-01 |
Zoetis Services Llc |
Composiciones de mycoplasma bovis.
|
WO2017040387A2
(fr)
|
2015-08-31 |
2017-03-09 |
Technovax, Inc. |
Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
|
EP3402878A1
(fr)
|
2016-01-11 |
2018-11-21 |
Zoetis Services LLC |
Nouvelles compositions vaccinales à protection croisée pour le virus de la diarrhée épidémique porcine
|
EP3430039A1
(fr)
|
2016-03-14 |
2019-01-23 |
Universitetet I Oslo |
Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
|
WO2017158421A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines anti-virales synthétiques
|
WO2017201390A1
(fr)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Nouvelles compositions adjuvantes
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
EP3471761A2
(fr)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Fragments de vaccin de liaison à hla et leurs utilisations
|
EP3474890A1
(fr)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Composition de conjugué polysaccharide pneumococcique-protéine
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
WO2018096396A1
(fr)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Variants d'albumine et leurs utilisations
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
US10525119B2
(en)
|
2017-03-31 |
2020-01-07 |
Boston Medical Center Corporation |
Methods and compositions using highly conserved pneumococcal surface proteins
|
ES2967001T3
(es)
|
2017-06-23 |
2024-04-25 |
Affinivax Inc |
Composiciones inmunogénicas
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
EP3574915A1
(fr)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Produit immunogène comprenant de l'il-4 et/ou de l'il-13 pour traiter des troubles associés à une expression ou une activité aberrantes de l'il-4 et/ou de l'il-13
|
CA3148824A1
(fr)
|
2019-07-31 |
2021-02-04 |
Sanofi Pasteur Inc. |
Compositions de conjugues de polysaccharide-proteine pneumococcique multivalents leurs methodes d'utilisation
|
WO2021141456A1
(fr)
|
2020-01-10 |
2021-07-15 |
주식회사 엘지화학 |
Composition comprenant une cellule présentant un antigène co-exprimant un complexe majeur d'histocompatibilité (cmh) et un antigène tumoral et traitement du cancer l'utilisant
|
NL2030835B1
(en)
|
2020-01-24 |
2022-12-29 |
Aim Immunotech Inc |
Methods, compositions, and vaccinces for treating a virus infection
|
EP4136219A1
(fr)
|
2020-04-16 |
2023-02-22 |
Par'Immune SAS |
Protéines gst 28 kda provenant de schistosomes et destinées au traitement de la vasculite
|
EP3900739A1
(fr)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
|
EP4213874A1
(fr)
|
2020-09-17 |
2023-07-26 |
Neovacs |
Produit immunogène comprenant un fragment d'ige pour le traitement de troubles inflammatoires médiés par l'ige
|
US20240156935A1
(en)
|
2021-03-31 |
2024-05-16 |
Vib Vzw |
Vaccine Compositions for Trypanosomatids
|
WO2024069420A2
(fr)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Compositions immunogènes comprenant un trimère de protéine f rsv
|